Insulin pen makers roll out new promos

Share this article:
Insulin pen makers roll out new promos
Insulin pen makers roll out new promos
Sanofi-Aventis US is rolling out a consumer campaign for its Lantus SoloStar pen aimed at getting people with type 2 diabetes to think differently about insulin.
 
Dubbed “I Chose,” the effort is launching with print ads and a website (WhyInsulin.com). TV ads will launch later in the year, as will social media components. Euro RSCG Life is handling creative.

The key insight behind the campaign, said Charlene Leitner, senior director, diabetes marketing at Sanofi-Aventis US, was that negative impressions of insulin impede many sufferers from getting the treatment they need.

“Many are fearful even to start insulin, so they just avoid going on it when they may not have an A1C level that's in control” said Leitner. “

The website features testimonials from patients who overcame their reluctance to use insulin to manage their diabetes.

Meanwhile, Novo Nordisk launched an online photo contest to promote its FlexPen, inviting users to submit photos showing the paces they've taken the device. In keeping with the franchise's racing theme, the grand prize is a trip to the Firestone Indy Lights Championship Race in Miami, FL. Users can submit their pics at WhereHaveYouFlexed.com through July 18, and visitors to the site can vote on contest entries between August 8 and 29. There's also a Race Charlie Kimball game and video featuring the racecar driver, who has type 1 diabetes and drives the No. 26 Levemir FlexPen car.

Creative for the campaign was handled by Big Communications, while PR was handled by Marina Maher Communications.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...